Abstract:The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause for the ongoing global public health emergency. It is more commonly known as coronavirus disease 2019 (COVID-19); the pandemic threat continues to spread aroundthe world with the fluctuating emergence of its new variants. The severity of COVID-19 ranges from asymptomatic to serious acute respiratory distress syndrome (ARDS), which has led to a high human mortality rate and disruption of socioeconomic well-being. For the restoration of pre-pandemic normalcy, the international scientific community has been conducting research on a war footing to limit extremely pathogenic COVID-19 through diagnosis, treatment, and immunization. Since the first report of COVID-19 viral infection, an array of laboratory-based and point-of-care (POC) approaches have emerged for diagnosing and understanding its status of outbreak. The RT-PCR-based viral nucleic acid test (NAT) is one of the rapidly developed and most used COVID-19 detection approaches. Notably, the current forbidding status of COVID-19 requires the development of safe, targeted vaccines/vaccine injections (shots) that can reduce its associated morbidity and mortality. Massive and accelerated vaccination campaigns would be the most effective and ultimate hope to end the COVID-19 pandemic. Since the SARS-CoV-2 virus outbreak, emerging biotechnologies and their multidisciplinary approaches have accelerated the understanding of molecular details as well as the development of a wide range of diagnostics and potential vaccine candidates, which are indispensable to combating the highly contagious COVID-19. Several vaccine candidates have completed phase III clinical studies and are reported to be effective in immunizing against COVID-19 after their rollout via emergency use authorization (EUA). However, optimizing the type of vaccine candidates and its route of delivery that works best to control viral spread is crucial to face the threatening variants expected to emerge over time. In conclusion, the insights of this review would facilitate the development of more likely diagnostics and ideal vaccines for the global control of COVID-19.

Engineering Antiviral Vaccines

Molecular engineering tools for the development of vaccines against infectious diseases: current status and future directions

Advanced Materials for SARS‐CoV‐2 Vaccines

Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants

Advances in the Design and Development of SARS-CoV-2 Vaccines

Viral Vector Vaccine Development and Application during the COVID-19 Pandemic

Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination against Infectious Diseases

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

Advanced technologies for the development of infectious disease vaccines

Nano-based approaches in the development of antiviral agents and vaccines

COVID-19 vaccine development and a potential nanomaterial path forward

Nanotechnology Platform for Advancing Vaccine Development against the COVID-19 Virus

Emerging vaccine nanotechnology: From defense against infection to sniping cancer

Engineering Materials and Devices for the Prevention, Diagnosis, and Treatment of COVID-19 and Infectious Diseases

Advances in Post-Pandemic Viral Antigen Production for Vaccines

Integration of Novel Materials and Advanced Genomic Technologies into New Vaccine Design

Recent Advances in Designing Adeno-Associated Virus-Based Vaccines Against Viral Infections

Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms

Recent Advances in Nanotechnology-Based COVID-19 Vaccines and Therapeutic Antibodies

Advances in gene-based vaccine platforms to address the COVID-19 pandemic

Emerging viruses and current strategies for vaccine intervention